CDK4/6 Inhibition as Maintenance and Combination Therapy for High Grade Serous Ovarian Cancer

Oncotarget - United States
doi 10.18632/oncotarget.24585
Full Text
Abstract

Available in full text

Categories
Oncology
Date
Authors
Publisher

Impact Journals, LLC

Related search

Targeting IDH1 as a Pro-Senescent Therapy in High-Grade Serous Ovarian Cancer

Molecular Cancer Research
Cancer ResearchOncologyMolecular Biology
2019English

New in High Grade Serous Ovarian Cancer Treatment

Effective Pharmacotherapy
2019English

Nadir CA-125 Level as Prognosis Indicator of High-Grade Serous Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2013English

PARP Inhibitors in Platinum-Sensitive High-Grade Serous Ovarian Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

CBX2 Identified as Driver of Anoikis Escape and Dissemination in High Grade Serous Ovarian Cancer

Oncogenesis
Cancer ResearchMolecular Biology
2018English

Low-Stage High-Grade Serous Ovarian Carcinomas

International Journal of Gynecological Pathology
GynecologyForensic MedicinePathologyObstetrics
2016English

Molecular Abnormalities in Ovarian Cancer Subtypes Other Than High-Grade Serous Carcinoma

Journal of Oncology
Oncology
2010English

Proteome Profiling of Low Grade Serous Ovarian Cancer

Journal of Ovarian Research
GynecologyOncologyObstetrics
2019English

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer

Frontiers in Oncology
Cancer ResearchOncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy